Verma Abhimanyu sold $35K of SOPH
Verma Abhimanyu (Chief Technology Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $6.95 on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and post-transaction holdings by the CTO, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but there is no accompanying fundamental catalyst in the text.
What to watch
The filing does not disclose reasons for sale beyond the plan; without follow-on purchases or guidance changes, trading impact should be limited.
Background
The article is a SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA.
Ticker impact
SOPHiA GENETICS CTO Verma Abhimanyu sold 5,000 shares in an open-market transaction at $6.9543 on 2026-08-04 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and provides no new company-specific operational or financial information.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales under 10b5-1 can be purely mechanical (tax or diversification) and may not reflect bearish expectations.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider transaction was disclosed on Form 4.
- insiderVerma Abhimanyu
Chief Technology Officer who sold shares under a 10b5-1 plan.
